S&T Bank’s Moderna MRNA Stock Holding History

S&T Bank’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-176	Closed	-$4.86K	–	515
2025 Q2	$4.86K	Hold	176	–	–	﹤0.01%	291
2025 Q1	$4.99K	Buy	+176	New	+$6.25K	﹤0.01%	271

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

S&T Bank's MRNA Position: Q3 2025 in Review

S&T Bank sold out of Moderna (MRNA) in Q3 2025, closing a stake of 176 shares — an estimated $4.86K sold.

S&T Bank first reported a position in MRNA in Q1 2025 and held it in 2 quarters. The position peaked at $4.99K in Q1 2025. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

S&T Bank reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
S&T Bank sold 176 Moderna shares in Q3 2025, an estimated $4.86K.
S&T Bank first reported a position in Moderna in Q1 2025 and held it in 2 quarters.
S&T Bank's Moderna position peaked at $4.99K in Q1 2025.
643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on S&T Bank's 13F filing for Q3 2025, filed 14 Nov 2025.